NetworkNewsBreaks – Genprex, Inc. (NASDAQ: GNPX)
Post# of 231
(Total Views: 323)
Posted On: 09/21/2020 3:22:41 PM
NetworkNewsBreaks – Genprex, Inc. (NASDAQ: GNPX) Appoints Seasoned Biotech Executive to Advance Expanding IP Estate
Genprex (NASDAQ: GNPX), a clinical-stage gene therapy company developing potentially life-changing technologies for patients with cancer and diabetes, today announced it has named Thomas C. Gallagher, Esq. as its senior vice president of Intellectual Property and Licensing. According to the update, Gallagher has extensive experience in the area of biotechnology intellectual property (“IP”) law, business development and licensing transactions with industry and academic institutions. “Mr. Gallagher will play a critical role in advancing our expanding intellectual property estate by spearheading IP strategy, which is an important element of the company’s overall success and value creation,” said Genprex president and CEO Rodney Varner in the press release. “A seasoned biotech executive, he will provide significant support as we execute on broadening our research and development programs, explore opportunities for partnerships on our existing programs, and opportunistically acquire new technologies to further expand our pipeline.”
Please see full disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer
Genprex (NASDAQ: GNPX), a clinical-stage gene therapy company developing potentially life-changing technologies for patients with cancer and diabetes, today announced it has named Thomas C. Gallagher, Esq. as its senior vice president of Intellectual Property and Licensing. According to the update, Gallagher has extensive experience in the area of biotechnology intellectual property (“IP”) law, business development and licensing transactions with industry and academic institutions. “Mr. Gallagher will play a critical role in advancing our expanding intellectual property estate by spearheading IP strategy, which is an important element of the company’s overall success and value creation,” said Genprex president and CEO Rodney Varner in the press release. “A seasoned biotech executive, he will provide significant support as we execute on broadening our research and development programs, explore opportunities for partnerships on our existing programs, and opportunistically acquire new technologies to further expand our pipeline.”
Please see full disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer
(0)
(0)Genprex Inc. (GNPX) Stock Research Links
Scroll down for more posts ▼